Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

0.7572 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11
Open 0.7572
Bid (Size) 0.7001 (11)
Ask (Size) 0.7600 (1)
Prev. Close 0.7572
Today's Range 0.7572 - 0.7572
52wk Range 0.4500 - 3.249
Shares Outstanding 44,959,548
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
-72.76%
-72.76%
1 Month
+15.11%
+15.11%
3 Month
-25.76%
-25.76%
6 Month
-60.15%
-60.15%
1 Year
-64.03%
-64.03%

More News

Read More
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Via Benzinga
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
From Cue Biopharma, Inc.
Via GlobeNewswire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Via InvestorPlace
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.